{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:09:45Z","timestamp":1761494985858,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.clim.2019.108296","type":"journal-article","created":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T03:25:34Z","timestamp":1572751534000},"page":"108296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Neoantigen-activated haploidentical T cell therapy for angioimmunoblastic T-cell lymphoma"],"prefix":"10.1016","volume":"210","author":[{"given":"Yuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haimei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyue","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.clim.2019.108296_bb0005","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.clim.2019.108296_bb0010","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","article-title":"Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project","volume":"31","author":"Federico","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.clim.2019.108296_bb0015","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.clim.2019.108296_bb0020","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdf033","article-title":"Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin\u2019s lymphoma classification project","volume":"13","author":"Rudiger","year":"2002","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.clim.2019.108296_bb0025","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.clim.2019.108296_bb0030","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.clim.2019.108296_bb0035","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.clim.2019.108296_bb0040","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann. Oncol."},{"issue":"91","key":"10.1016\/j.clim.2019.108296_bb0045","first-page":"37","article-title":"Immunotherapy with chimeric antigen receptors for multiple myeloma","volume":"17","author":"Garfall","year":"2014","journal-title":"Discov. Med."},{"key":"10.1016\/j.clim.2019.108296_bb0050","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/imr.12243","article-title":"Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies","volume":"263","author":"Gill","year":"2015","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.clim.2019.108296_bb0055","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/PPO.0000000000000032","article-title":"CAR T cells for solid tumors: armed and ready to go?","volume":"20","author":"Kakarla","year":"2014","journal-title":"Cancer J."},{"issue":"23","key":"10.1016\/j.clim.2019.108296_bb0060","first-page":"6050","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"CU","year":"2015","journal-title":"Blood."},{"issue":"32","key":"10.1016\/j.clim.2019.108296_bb0065","doi-asserted-by":"crossref","first-page":"E439","DOI":"10.1200\/JCO.2012.47.7521","article-title":"Tumor exome analysis reveals Neoantigen-specific T-cell reactivity in an Ipilimumab-responsive melanoma","volume":"31","author":"Van","year":"2013","journal-title":"J. Clin. Oncol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618307058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618307058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:01:13Z","timestamp":1761494473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661618307058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":13,"alternative-id":["S1521661618307058"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2019.108296","relation":{},"ISSN":["1521-6616"],"issn-type":[{"type":"print","value":"1521-6616"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoantigen-activated haploidentical T cell therapy for angioimmunoblastic T-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2019.108296","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108296"}}